3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Other solid neoplasm
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
121
Lung Neoplasms
49
Triple Negative Breast Neoplasms
35
Breast Neoplasms
33
Small Cell Lung Carcinoma
29
Squamous Cell Carcinoma of Head and Neck
24
Ovarian Neoplasms
24
Neoplasm Metastasis
21
Fallopian Tube Neoplasms
19
Endometrial Neoplasms
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
15
Head and Neck Neoplasms
12
Colorectal Neoplasms
11
Carcinoma
10
Oropharyngeal Neoplasms
9
Esophageal Neoplasms
9
Urinary Bladder Neoplasms
8
Prostatic Neoplasms
8
Carcinoma, Transitional Cell
8
Pancreatic Neoplasms
7
Carcinoma, Squamous Cell
7
Carcinoma, Ovarian Epithelial
6
Adenocarcinoma of Lung
6
Uterine Cervical Neoplasms
5
Mouth Neoplasms
5
Mesothelioma
5
Lung Diseases
5
Laryngeal Neoplasms
5
Respiratory Tract Neoplasms
4
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
VMBP protocol
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Carboplatin
×
90 days
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled